For more information call (888) LUHS-888.
Patients must be 18 years or older and have histologically confirmed malignant melanoma that is metastatic or unresectable and the following:
-Eligible to receive high-dose IL-2 per institutional guidelines.
-A tissue block available with adequate tumor to perform RNA extraction and DASL analysis (Patients with only a previous fine-needle
aspirate are ineligible for enrollment).
-Willing to donate a small amount of whole blood prior to treatment for laboratory analysis.
-Must give informed consent prior to initiation of therapy.
-Must be ambulatory with good performance status (ECOG 0 or 1).
The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information ( for example cancer diagnosis and history, prior treatments for cancer, etc.), blood and tumor samples prior to treatment and tumor measurements after treatment.